

# SCRI Trials and Trial Regimen Updates

The following updates were completed between Aug. 23, 2024, through Sept. 20, 2024. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact [SCRiKMEMRedits@McKesson.com](mailto:SCRiKMEMRedits@McKesson.com).

## New Builds Completed

Study Number	Notes for New Build
23337	USOR 23337 MEL 74 Phase 2/3 Comparator Arm Dacarbazine Q21D USOR 23337 MEL 74 Phase 2/3 Comparator Arm Ipilimumab + Nivolumab Q21D USOR 23337 MEL 74 Phase 2/3 Comparator Arm Maintenance Nivolumab Q28D USOR 23337 MEL 74 Phase 2/3 Comparator Arm Pembrolizumab Q21D USOR 23337 MEL 74 Phase 2/3 Treatment Arm IDE196 (Darovasertib) + Crizotinib Q21D
23335	USOR 23335 MEL 81 Phase 3 Arm A Fianlimab + Cemiplimab Q21D USOR 23335 MEL 81 Phase 3 Arm B Nivolumab + Relatlimab (Opdualag) Q28D

Study Number	Notes for New Build
23306	<p>USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part A Maintenance I-DXd + Atezolizumab Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Induction Etoposide + Atezolizumab + Carboplatin Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Maintenance Arm 1 I-DXd + Atezolizumab Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 1 Part B Maintenance Arm 2 I-DXd + Atezolizumab Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part A Induction I-DXd + Atezolizumab + Carboplatin Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part A Maintenance I-DXd + Atezolizumab Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Induction Arm 3 I-DXd + Atezolizumab + Carboplatin Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Induction Arm 4 I-DXd + Atezolizumab + Carboplatin Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Maintenance Arm 3 I-DXd + Atezolizumab Q21D</p> <p>USOR 23306 LUN 553 Phase 1B/2 Cohort 2 Part B Maintenance Arm 4 I-DXd + Atezolizumab Q21D</p>
23333	<p>USOR 23333 MPN 20 Phase 3 Randomized Navtemadlin or Placebo D1-7 + Ruxolitinib Q28D</p> <p>USOR 23333 MPN 20 Phase 3 Run-in Monotherapy Ruxolitinib Q28D</p>
22273	<p>USOR 22273 LYM 238 Phase 3 Arm A Zanubrutinib + Obinutuzumab D1,8,15 fb D1 Q28D</p> <p>USOR 22273 LYM 238 Phase 3 Arm B Rituximab D1,8,15,22 fb D1 + Lenalidomide Q28D</p> <p>USOR 22273 LYM 238 Phase 3 Arm C Zanubrutinib + Rituximab D1,8,15,22 fb D1 Q28D</p> <p>USOR 22273 LYM 238 Phase 3 Arm D Rituximab D1,8,15,22 fb D1 + Lenalidomide Q28D</p>

Study Number	Notes for New Build
24004	USOR 24004 HN 33 Phase 3 Cetuximab D1,8,15,22 Q28D USOR 24004 HN 33 Phase 3 Docetaxel D1,8,15,22 Q28D USOR 24004 HN 33 Phase 3 Methotrexate D1,8,15,22 Q28D USOR 24004 HN 33 Phase 3 Petosemtamab D1,15 Q28D
23234	USOR 23234 Arm A Volrustomig Q21D
24026	USOR 24026 BRE 440 Phase 1b/2 Dose Escalation RYZ101 Q42D
24063	USOR 24063 GU 241 Phase 2 Cohort A Vudalimab (XmAb20717) + Carboplatin + Cabazitaxel Q28D USOR 24063 GU 241 Phase 2 Cohort E Vudalimab (XmAb20717) + Docetaxel Q28D
23304	USOR 23304 Multi 84 Phase I Part 1 Dose Escalation TORL-1-23 Q21D
23170	USOR 23170   LUN 543   Phase 3   Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 23170   LUN 543   Phase 3   Pembrolizumab + Pemetrexed + Cisplatin Q21D USOR 23170   LUN 543   Phase 3   Zongertinib (PO; Daily) Q21D USOR 23170   LUN 543   Phase 3   BI 1810631 Q21D USOR 23170   LUN 543   Phase 3   Pemetrexed Premedications

### Updated Reference Information

Study Number	Updated Reference Information
22325	PA3, 04Jun2024
22106	PA V3.0
23288	Dose escalation memo 1.8 to 2.7mg, 14Jun2024
22003	PAv10.0, 05Jun2024

Study Number	Updated Reference Information
22322	PA vD, 02/09/2024 PA vE, 04/12/2024
22106	PA v3.0
21270	DIL: Azenosertib 21Jun2024
19062	PA4.0 Pharmacy Manual v6
23292	V16.1
23212	PA v3.0, 28 May 2024
23048	csp-v4
21365	V4 18JUN24
23120	V7.2 20JUN2024
22298	V8 11JUN2024
23170	V3.0
22133	v3.0_26Jun2024
23292	PA V17
22093	PA 9 13Aug2024